ABUSArbutus Biopharma Corporation

1. Aug 21, 2026On August 21, 2026, Arbutus Biopharma Corporation (the “Company”) issued a press release announcing its plans to launch a modified “Dutch auction” tender offer to purchase up to US$230 million in value of its common shares, at a price ranging from US$5.00 to US$5.75.Other event · Form 8-K
2. Aug 12, 2026Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update.Earnings release · press release
3. Jul 16, 2026In March 2025, Arbutus Biopharma Corporation (“Arbutus” or the “Company”) entered into an agreement (the “RSV Agreement”) with Genevant Sciences GmbH (“Genevant”) that provided that Arbutus would be entitled to any award of damages in, or proceeds from the settlement of, certain patent litigation against Moderna, Inc. …Material agreement terminated · Form 8-K
4. May 27, 20262026 Omnibus Share and Incentive Plan On May 26, 2026, Arbutus Biopharma Corporation (the “Company”) held its 2026 Annual General and Special Meeting of Shareholders (the “Annual Meeting”)Director or officer change · Form 8-K
5. May 13, 2026Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update.Earnings release · press release
6. Apr 15, 2026On April 15, 2026, Arbutus Biopharma Corporation issued a press release announcing that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation for imdusiran for the treatment of chronic hepatitis B. The FDA’s Fast Track program is designed to facilitate the development and expedite the review …Other event · Form 8-K
7. Mar 23, 2026Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update.Earnings release · press release
8. Mar 3, 2026On March 3, 2026 (the “Effective Date”), Arbutus Biopharma Corporation (“Arbutus” or the “Company”), Genevant Sciences GmbH (“Genevant” and together with Arbutus, “Arbutus/Genevant”), and, solely for certain purposes, Genevant Sciences Ltd., and Moderna, Inc. and ModernaTx, Inc. (together, “Moderna”) entered into a …Material agreement entered · Form 8-K
9. Feb 20, 2026On February 17, 2026, the U.S. District Court for the District of Delaware issued a memorandum and order in the litigation filed by Arbutus Biopharma Corporation (the “Company”) and its licensee, Genevant Sciences GmbH (collectively with its affiliates, “Genevant”), against Moderna Inc. and a Moderna affiliate …Other event · Form 8-K
10. Feb 6, 2026On February 2, 2026, the U.S. District Court for the District of Delaware issued a memorandum and order in the litigation filed by Arbutus Biopharma Corporation (the “Company”) and its licensee, Genevant Sciences GmbH (collectively with its affiliates, “Genevant”), against Moderna Inc. and a Moderna affiliate …Other event · Form 8-K
11. Jan 16, 2026On January 15, 2026, the Board of Appeal of the European Patent Office (“EPO”) revoked Arbutus Biopharma Corporation’s (the “Company’s”) European patent EP 2279254 (the “’254 Patent”)Other event · Form 8-K
12. Dec 11, 2025On December 11, 2025, Lindsay Androski, Chairperson, Chief Executive Officer and President of Arbutus Biopharma Corporation (the “Company”) will give a presentation regarding the Company’s ongoing lawsuits against Moderna Therapeutics, Inc., Pfizer Inc. and BioNTech SE, for their use of the Company’s patented lipid …Other event · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.